Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 1.00 |
| ▸ | MMP2 | P08253 | 10/20 | 1.00 |
| ▸ | MMP9 | P14780 | 10/20 | 1.00 |
| ▸ | EGFR | P00533 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-O-Tolylcinnamamide SCHEMBL29844171 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9EGFRKDM4E | |
| N-O-Tolylcinnamamide SCHEMBL2593756 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9EGFRKDM4E | |
| N-O-Tolylcinnamamide SCHEMBL15902545 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL13352237 | 0.88 | MMP1 (0.78) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL27493724 | 0.88 | MMP1 (0.78) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL10492426 | 0.88 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAPT | |
| SCHEMBL10492424 | 0.88 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAPT | |
| SCHEMBL10492396 | 0.87 | MMP1 (0.77) | MMP1MMP2MMP9EGFRMAPT | |
| SCHEMBL10492394 | 0.87 | MMP1 (0.77) | MMP1MMP2MMP9EGFRMAPT | |
| SCHEMBL13675779 | 0.85 | MMP1 (0.74) | MMP1MMP2MMP9EGFRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160280651-A1 | COMPOUNDS THAT INDUCE ABA RESPONSES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-09-29 | — | — | US | disclosed |
| EP-3013800-A1 | COMPOUNDS THAT INDUCE ABA RESPONSES | The Regents of the University of California (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2016022915-A1 | 6-SULFONYLAMINO QUINOLINE COMPOUNDS AS PLANT GROWTH REGULATORS | THE REGENT OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-11 | — | — | WO | disclosed |
| CN-103221404-B | Can be used as the unsaturated nitrogen heterogeneous ring compound of PDE10 inhibitor | AMGEN INC. (US) | 2015-12-16 | — | — | CN | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| EP-2569300-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8097650-B2 | Method of treating a condition associated with phosphorylation of TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| EP-1671958-B1 | Method of producing amide compound | FUJIFILM CORP (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-20070259051-A1 | Method of treating a condition associated with phosphorylation of TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-11-08 | — | — | US | disclosed |
| EP-0524846-A1 | 2-(Piperidin-1-yl)ethanol derivatives, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259051-A1 | Method of treating a condition associated with phosphorylation of TASK-1 | TTBK1, PEAK1, TLK1 | MMP1 3263/4885MMP2 4679/4885MMP9 4765/4885 |
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | MMP1 19/4885MMP2 88/4885MMP9 119/4885 |
| US-20160280651-A1 | COMPOUNDS THAT INDUCE ABA RESPONSES | AAK1, BROX, BID | MMP1 4661/4885MMP2 4713/4885MMP9 4750/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MMP1 752/4885MMP2 2166/4885MMP9 1065/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MMP1 752/4885MMP2 2166/4885MMP9 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.